TAK-341 (MEDI1341)

Single-program entity page for the Takeda / MedImmune α-synuclein antibody TAK-341 (MEDI1341). Promoted from the therapeutic-programs Entity Backlog. Per-axis α-synuclein narrative continues to live on alpha-synuclein § Antibody and Immunotherapy Programs; this page collects the program-level evidence package across the two primary TAK-341 / MEDI1341 source pages and the three Pipeline-of-PD competitor-inventory pages that carry TAK-341 rows. Every substantive statement links back to a source note or the canonical by-photo Markdown. Where the source carries Uncertain Spans, that uncertainty is preserved here rather than smoothed out.

Program Overview

TAK-341 (MEDI1341) is a passive-immunotherapy α-synuclein monoclonal antibody program shared between Takeda and AstraZeneca / MedImmune. The corpus material covers two TAK-341 nav-rooted pages — a PK/PD model page and a Clinical studies page — plus three Pipeline-of-PD cross-pipeline pages that include TAK-341 / MEDI1341 in competitor comparison tables for aSyn antibody, aSyn small-molecule, and aSyn vaccine programs.

The PK/PD model page (20240722_181818) documents the antibody’s epitope, effector-function design, monomeric and aggregated KD measurements, the DELFIA Aggregated Capture ELISA (Figure 4), preclinical aSYN-spreading and MSA post-mortem data, the two-compartment plasma / CSF-brain PK/PD model (Figure 17), the predicted plasma profile and target-suppression curves at four IV doses (Figure 18), the Key PK/PD Model Parameters table (Table 6, including MEDI1341 brain penetration 0.1 %, MEDI1341 affinity 0.074 nM, Human alpha-syn basal levels in plasma 0.9 nM / brain 0.093 nM, Human t1/2 of alpha-syn in plasma / brain 240 h), and Planned MEDI1341 Dose Escalations with Predicted Cerebrospinal Fluid α-synuclein Suppression (Table 7, Cohort 1 70 mg → Cohort 5 4200 mg).

The Clinical studies page (20240722_181822) documents the program-vs-Prasinezumab comparator table at the top, the MEDI1341 MAD Mean (SD) % Change from Baseline for Free a-synuclein in CSF evidence figure (slide source 20220112 TAK-341 POM and Ph2 planning discussion - 011222), the TAK-341 rat / NHP preclinical free / total CSF α-syn evidence (Figure 14), the SAD HV study design (A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in HV), the αSYN-vs-341 CSF molarity / relative-concentration calculation (αSYN in CSF: 194.4 ng/L / MW 14500 → 1.34E-11 M (relative 6.19) ; 341 in CSF: 320.5 ng/L / MW 148000 → 2.17E-12 M (relative 1)), the MAD PD study design (Cohort 1 (1200 mg) / Cohort 2 (2400 mg) / Cohort 3 (4800 mg), N=12 per cohort (N=9 MEDI1341, N=3 placebo), three 60-minute IV infusions on Days 1, 29, 57), and the MSA Phase 2 study note (FPI in 202207, BM: NFL, interim futility / efficacy / sample-size re-estimation after ~40 % of subjects complete 52 weeks).

The three cross-pipeline competitor pages (20240722_184324, 20240722_184327, 20240722_184330) position TAK-341 / MEDI1341 inside the Pipeline-of-PD aSyn-Antibody / aSyn-Small molecules / aSyn-Vaccine inventory: the eight-program aSyn-Antibody comparison row (Prasinezumab / Cinpanemab / TAK-341 (MEDI1341) / Lu AF82422 / ABBV-0805 / Affitope PD01A / PD03A / UB-312) with epitope and development-status columns, the α-syn sequence targeted by mAbs and vaccines diagram with horizontal binding-range labels, the PASADENA Part 1 / Part 2 / Part 3 trial-design narrative for the comparator Prasinezumab, the Prothena/Roche prior P1 SAD/MAD CSF/serum ratio, the BIIB054 Cinpanemab P1 evidence, the ABL301 / Sanofi / ABL Bio Grabody-B bispecific data, the mAbs summary table (with the explicit TAK-341 (MEDI1341/Aslo452ngl-3) clone / sub-row), and the bottom- of-page MEDI1341 SAD-study PK table opener that continues into 20240722_184333 (see Source Scope And Boundary Notes below).

Source Scope And Boundary Notes

The 5-source set deviates from a strict “first nav_path entry == program nav root” rule in four specific places. Each is recorded here so the entity scope can be revisited if needed.

• 20240722_181818 carries Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model, so the program nav root is the second element rather than the first. This is the same pattern as the abutting Word page in the same Pipeline-of-GD-and-GBA-PD inherited-thread band; the page is fully included for evidence because the entire body covers TAK-341 / MEDI1341 mechanism, epitope, affinity, and PK/PD model content. The page does not appear in tak-341-medi1341 because the per-nav-root index keys on the first nav_path entry.
• 20240722_181822 carries TAK-341 (MEDI1341) > Clinical studies as its nav_path and is the only page indexed under the TAK-341 (MEDI1341) per-nav- root index (tak-341-medi1341). It is fully included for evidence.
• 20240722_184324, 20240722_184327, and 20240722_184330 carry first nav_path entries PDE / Pipeline of PD (not TAK-341 (MEDI1341)); they are included as cross-pipeline rows because the therapeutic-programs Program Matrix row for TAK-341 lists them under cross-pipeline rows and they each carry one or more TAK-341 / MEDI1341 row, sub-row, or PK-table opener. They are fully included for evidence but every claim is sourced to the cross-pipeline page, not back-projected onto the two primary TAK-341 pages above.
• 20240722_184333 is not included in this entity. The MEDI1341 SAD-study PK table that begins at the bottom of _184330 continues into _184333, but _184333 is a Pipeline of PD > GT page (its first nav_path entry is Pipeline of PD > GT) and is delegated to clinical-pd under the therapeutic-programs Programs Covered By Topic Pages Only Pipeline of PD GT row. The MEDI1341 PK table, the comparison of immediate post-infusion serum levels for TAK-341 (~200 µg/mL at 1200 mg, ~800 µg/mL at 4800 mg targeted dose) vs PD01A vaccine (~20 µg/mL), and the CSF fraction comparison (0.4–0.5 % for TAK-341 vs 0.3 % for this vaccine) all live on _184330 / _184333; readers consulting them should follow the related-photo continuation note on the _184330 source.

Adjacent material that is excluded from this entity:

• The α-synuclein Tier 1 page MSA aSyn in MSA > CSF aSyn in MSA (20240722_184156) contains the JS narrative line CSF aSyn 은 MSA 에서 정상과 차이가 없고, exosome aSyn 은 결과가 inconsistent 하니, 유용없으나, tak-341 의 response 로서 감소를 보는 의미는 있겠다. That MSA-context reference is owned by msa (cohort / diagnosis / outcome-measure / pathology) and by alpha-synuclein § MSA aSyn (Tier 1 source ownership), not by this entity page.
• The α-synuclein Tier 1 page aSyn programs > aSyn Propagation Suppressor (20240722_181827) contains the line TAK-341 IDP plan: if TAK-341 is shown to reduce αSYN spreading in the NHP model and that … inside the broader TAKEDA × Atuka lentivirus + α-syn Tg mice Old Portfolio Entry block. That umbrella page is the canonical owner of the aSyn programs umbrella and is delegated to the upcoming entities/programs/asyn-propagation-suppressor backlog candidate per therapeutic-programs; this page references it via Related Pages rather than re-narrating it.

Evidence Package

evidence area	source-captured detail	source
Mechanism and epitope	TAK-341 epitope at residues 102-130 of the C-terminal region of α-syn; epitope coded by exon 5 (absent in SNCA-112 and SNCA-98 isoforms which constitute a sizeable fraction of total aSYN); mechanism diagram with Phosphorylation / O-GlcNAcylation / Ubiquitination / Sumoylation / Truncation / Nitration site labels; α-syn full-length sequence with red exon-5 epitope and Pan-Syn / N-1&2 / NAC / NAC-1&2 / Syn-1 / Hu-Syn / NACP-C / A30P / A53T antibody-fragment annotations.	20240722_181818
Effector function	MEDI1341 is the only antibody without an effector function (202111 key events); aglycosylated IgG1 background note that natural human IgG1 N-glycan at Asn297 is indispensable for FcγR / C1q recognition and ADCC / ADCP / CDC effector functions.	20240722_181818
Affinity (monomer vs aggregate)	KD for monomeric human aSyn 106 pM (Octet) / 74 pM (KinExA solution-phase) / 174 pM (Fab, KinExA); aggregated aSyn affinity 37.3-930 pM (not substantially different than for monomeric); Capture-ELISA table Synuclein species × Ab concentration for immobilization × TAK-341 KD (M) × PRX002 KD (M) with monomer / oligomer rows; Figure 4 DELFIA Aggregated Capture ELISA Eu-counts vs Aggregate / Monomer / Blank for clones MEDI1341 / Aslo0543 / asyn0087; preserved JS aside Does this mean that tak-341 has stronger affinity to aggregated aSyn than to monomer? It seems not.	20240722_181818
Preclinical aSYN spreading and MSA postmortem	Reduced spreading of aSYN injected as a lentiviral vector into the hippocampus; comparator 9E4 (Prothena/Roche aSYN antibody) had no spreading effect; MSA postmortem brain IHC (2 PD, 3 MSA, 2 control) — both MEDI1341 (Aslo0452) and 4D6 antibodies demonstrated binding to GCIs in the brains of MSA patients (js: no quantification was done).	20240722_181818
PK/PD model (Figure 17)	Two-compartment plasma / CSF-brain model with Ksyn, Kon, Koff, Kdeg, Kint rate constants; plasma P and brain / CSF B mAb compartments; P+A-syn / B+A-syn complex compartments; transfer line mAb transfer to CSF/Brain.	20240722_181818
Predicted plasma profile and target suppression (Figure 18)	Predicted Median Plasma Profile after Single IV Dose Administration of MEDI1341 in Human; multi-dose (70 / 210 / 700 / 2100 / 4200 mg SD IV) plasma concentration vs time curves and α-syn suppression %; JS narrative 10일전까지 구간에서는 기본적으로 약농도와 aSyn suppression 정도가 같이 움직임. tak341's t1/2 is 25days. so we need q28day dosing. Syn t1/2 in plasma is 10 days. so 이때부터 suppression 정도 급 약화.	20240722_181818
Key PK/PD Model Parameters (Table 6)	Cynomolgus monkey clearance 0.12192 L/day, inter-compartmental clearance 0.13563 L/day, central / peripheral compartment volumes 0.30339 / 0.93872 L; Human body weight 70 Kg; MEDI1341 molecular weight 150000 Da; Human central / peripheral compartment volume 7.368 / 22.79 L; Human central compartment elimination rate 0.17 1/d; Human clearance 1.32 L/day; Human alpha-syn elimination rate from brain 0.17 1/d; Human inter-compartmental clearance 1.46 L/day; MEDI1341 brain penetration 0.1 %; MEDI1341 binding dissociation constant 3.3 1/d; MEDI1341 affinity 0.074 nM; Human t1/2 of alpha-syn in plasma 240 h; Human t1/2 of alpha-syn in brain 240 h; Human alpha-syn basal levels in plasma 0.9 nM; Human alpha-syn basal levels in brain 0.093 nM.	20240722_181818
Planned MEDI1341 Dose Escalations (Table 7)	Visible cohorts Cohort 1: 70 mg / 16 % suppression at Day 29 / 50 % at peak and Cohort 5: 4200 mg / 90 % suppression at Day 29 / 98 % at peak; intermediate cohort rows are not visible in this photo and likely require adjacent photo evidence; All doses will be administered by intravenous infusion.	20240722_181818
Comparator-program top-of-page table (TAK-341 vs Prasinezumab)	Top table row strip with Prasinezumab SAD HV iv ↓ 96 %, Prasinezumab MAD PD iv 0.3 (w9) ↓ 97 % (the highest dose); monomeric a-syn in CSF did not change (due to its low affinity to monomeric aSyn). At the time, Prothena had no assay for a-syn aggregates in CSF; TAK-341 P2 (MSA): This assay (MSD) was used in SAD and MAD studies and will be set up the same fashion to support ph2 in MSA (priority); TAK-341 MAD PD; TAK-341 SAD HV iv rows (top/left edge of table is cut off; preserved verbatim).	20240722_181822
MEDI1341 MAD CSF aSyn suppression evidence (POM Ph2 planning)	Mean (SD) % Change from Baseline for Free a-synuclein in CSF Following Multiple Intravenous Doses of MEDI1341 or Placebo; slide source 20220112 TAK-341 POM and Ph2 planning discussion - 011222; O-D(?) the fraction of aSYN that can bind TAK-341 is slightly <50% of the total in human; visible MAD dose rows 1200 mg, 2400 mg, 4800 mg, 4500 mg with serum / Cmax / aSyn fragments and partial percent-change values (-47.2 / -47.3 %, -68.9 / -68.1 %, -86.5 %).	20240722_181822
TAK-341 preclinical rat / NHP CSF a-syn evidence (Figure 14)	rat / WT / iv / 1w / 13w and NHP / WT / iv / 1w / 13w paired panels; Free α-synuclein in rat: rapid & robust suppression; Rat Total α-synuclein (Study AB21095 [BS001397-80]): no change; Rat Free α-synuclein (Study AB21095 [BS001397-80]); Monkey Total α-synuclein (Study AB21096 [BS001397-85]): no change; Monkey Free α-synuclein (Study AB21096 [BS001397-85]) with Cyno CSF Concentration 132, 293, 760 ng/mL; NOAEL exposure note Within the planned human dose range of 70 to 4200 mg, it is not anticipated that the maximum exposure will exceed a Cmax of 2800 ng/mL or an AUC∞ of 4100 ng*day/mL, the exposure achieved at the NOAEL in cynomolgus monkeys.	20240722_181822
SAD HV study	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in HV; PK/PD modelling objectives ① examine the historic PK/PD prediction based on monkey data, ② estimate the extent of free CSF aSYN reduction in the subsequent cohorts, and ③ determine if the modification of the SAD and/or MAD design is needed to capture the full PK/PD relationship.; result note [results] At 4500 mg, there is slightly more aSYN than TAK-341.	20240722_181822
Molarity / relative concentration calculation (CSF)	αSYN in CSF: A=194.4 ng/L / MW B=14500 → A/B=1.34E-11 (0.013407) / relative conc 6.19; 341 in CSF: A=320.5 ng/L / MW B=148000 → A/B=2.17E-12 (0.002166) / relative conc 1; definitional note Molarity=A/B=the moles of a solute (molecule)/L = the molar concentration of a solution.	20240722_181822
MAD PD study (design and biomarker plan)	PD, iv, 8w DB treatment period. Each subject will receive three 60-minute intravenous infusions of MEDI1341 or placebo during the treatment period, with 4 weeks between infusions (1 infusion on each of Days 1, 29, and 57); milestone (20190613 scenario 1, POM=e POC): ↓ >50% CSF Asyn (at trough concentration of drug) # 성공여부는 50%감소로 하지만, 2상 dose는 maximal reduction 일으키는 dose로 하겠다는 것.; PK/PD modelling objectives ① predict the relationship of free CSF aSYN to TAK-341 exposure at steady state, ② estimate the dose regimens that provide maximal free CSF aSYN reduction, and ③ facilitate dose selection for planned phase 2/3 trials in PD and MSA indications.; cohort table Cohort 1 (1200 mg) / DEC data review / Cohort 2 (2400 mg) / DEC data review / Cohort 3 (4800 mg), N=12 per cohort (N=9 MEDI1341, N=3 placebo); secondary α-syn levels (total in plasma, free in cerebrospinal fluid); tertiary MDS-UPDRS assessments; CSF sampling baseline day -49 to -2, day 61, day 85; exploratory blood / CSF biomarkers RNA (transcript / microRNA), proteins (synaptic, oligomeric α-syn, p-aSyn, α-syn fragments, exosomal proteins, tau, amyloid 1-42, broad proteomics), and metabolomics / lipidomics.	20240722_181822
MSA Phase 2 study	An interim analysis for possible futility and/or efficacy analysis and/or sample size re-estimation may be conducted after approximately 40% of subjects have completed 52 weeks of treatment; FPI in 202207; BM: NFL.	20240722_181822
Pipeline-of-PD aSyn-Antibody competitor table	Eight-program comparison row (Prasinezumab / Cinpanemab / TAK-341 (MEDI1341) / Lu AF82422 / ABBV-0805 / Affitope PD01A / Affitope PD03A / UB-312) with target / mechanism / design / results / epitope / development-status columns; α-syn sequence targeted by mAbs and vaccines diagram description with horizontal binding-range labels (Cinpanemab N-term region, Prasinezumab, MEDI1341, Lu AF82422, ABBV-0805 C-term cluster, PD01A, UB-312 further C-term); Nitrase NITROME nitrated-α-syn antibody preclinical narrative.	20240722_184324
PASADENA trial-design narrative (comparator)	Prasinezumab (PRX002 / RG7935 / RO7046015 / 9E4) PASADENA Part 1 / Part 2 / Part 3 N=316 design (1500 mg vs 4500 mg High dose / 3500 mg < 65 kg, IV Q4W, DaT-SPECT timeline anchors); mAbs summary table with Prasinezumab and TAK-341 (MEDI1341/Aslo452ngl-3) rows; aSyn-Small molecules row tail (UCB0599 / minzasolmin "ORCHESTRA" NCT04658186 P2); preserved as cross-pipeline reference.	20240722_184327
Pipeline-of-PD aSyn-Vaccine + MEDI1341 PK table opener	aSyn - Vaccine table tail (NPT200-11 Neuropore aS aggregation inhibitor; Anle138b MODAG / TEVA; Ionis; PD1601 / PD1602 BioArctic / AbbVie); AC Immune PD01A (ACI-7104) and PD03A AFFiRiS active-immunotherapy program (P2 VacSYn / NCT06015841 adaptive design, P1 MSA / NCT02270489, P1 NCT01568099 / sPD); AFF008 study series figure (3 embedded image assets); CSF Oligo-aSyn / MDS-UPDRS III correlation block (r = 0.515 oligo-α-syn vs baseline MDS-UPDRS Part 3, p = 0.020); SAD study - PK data to date MEDI1341 PK table opener (Dose increment / Cmax / DPF Cmax / AUC₀-∞ / DPF AUC at 70 / 210 / 400 / 1200 mg) — table continues into 20240722_184333 per the source’s related_photos continuation note.	20240722_184330

Key Source Interpretations

interpretation	source
TAK-341 / MEDI1341 binds an epitope coded by exon 5 (residues 102-130, near C-terminal); the exon-5-coded epitope is absent from the SNCA-112 and SNCA-98 isoforms, which are described in source as constituting a sizeable fraction of total aSYN. The source records this as a quoted line from the MEDI1341 Investigator’s Brochure rather than as a derived statement.	20240722_181818
TAK-341 is engineered as the only antibody in the source’s comparator set without effector function (aglycosylated IgG1 background, no FcγR / C1q recognition, no ADCC / ADCP / CDC); the source records this as a 202111 key events line and explains the IgG1 N297 glycosylation requirement in parentheses as background, not as a derived claim.	20240722_181818
Source-recorded affinity does not differentiate monomeric from aggregated aSyn beyond a narrow window: monomer KD is 106 pM (Octet) / 74 pM (KinExA) while aggregated KD is 37.3-930 pM. The source explicitly preserves the JS aside Does this mean that tak-341 has stronger affinity to aggregated aSyn than to monomer? It seems not. rather than asserting monomer-vs-aggregate selectivity.	20240722_181818
The PK/PD model is parameterised against cynomolgus-monkey PK and human α-syn elimination rates; key human-side parameters are MEDI1341 brain penetration 0.1 %, MEDI1341 affinity 0.074 nM, Human alpha-syn basal levels in plasma 0.9 nM, brain 0.093 nM, and Human t1/2 of alpha-syn in plasma / brain 240 h.	20240722_181818
Predicted CSF α-synuclein suppression in source spans Cohort 1 70 mg → 16 % at Day 29 / 50 % at peak to Cohort 5 4200 mg → 90 % at Day 29 / 98 % at peak; intermediate cohort rows are noted as not visible in the source photo and the source flags them as a likely adjacent-photo follow-up.	20240722_181818
The MAD PD POM gate is defined in source as ↓ >50% CSF Asyn (at trough concentration of drug), with the explicit JS clarification that 성공여부는 50%감소로 하지만, 2상 dose는 maximal reduction 일으키는 dose로 하겠다는 것 — i.e., success criterion is 50 % reduction but the Phase 2 dose is intended to be the maximal-reduction dose, not the threshold dose.	20240722_181822
The MAD PD CSF-sampling schedule is baseline day -49 to -2 / day 61 / day 85 with three 60-minute IV infusions on Days 1, 29, and 57; exploratory CSF / blood biomarker scope spans transcript / microRNA RNA, synaptic / oligomeric α-syn / p-aSyn / α-syn fragments / exosomal protein / tau / amyloid 1-42 protein, and broad proteomics / metabolomics / lipidomics.	20240722_181822
The molarity calculation in source records that αSYN in CSF (relative concentration 6.19) is approximately 6× molar excess over 341 in CSF (relative concentration 1) at the captured CSF observation, computed from 194.4 ng/L (αSYN, MW 14500) vs 320.5 ng/L (341, MW 148000).	20240722_181822
The MSA Phase 2 study uses NFL as biomarker (BM: NFL) and includes an interim futility / efficacy / sample-size re-estimation analysis after ~40 % of subjects have completed 52 weeks of treatment; FPI is recorded as 202207 (preserved verbatim — 2022-07 shorthand is the most likely reading per the source’s Uncertain Spans note).	20240722_181822
The Pipeline-of-PD aSyn-Antibody page positions TAK-341 / MEDI1341 inside an eight-program comparator inventory (Prasinezumab / Cinpanemab / TAK-341 / Lu AF82422 / ABBV-0805 / PD01A / PD03A / UB-312); the visible row on _184327 records the sub-clone label (MEDI1341/Aslo452ngl-3) and is the source’s connection point between the TAK-341 / MEDI1341 program nav-root and the broader Pipeline-of-PD competitor map.	20240722_184324, 20240722_184327

Source Table

stem	nav path	source note	canonical	uncertain spans	embedded images
20240722_181818	Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model	note	md	7	4
20240722_181822	TAK-341 (MEDI1341) > Clinical studies	note	md	7	2
20240722_184324	PDE > PIAS2 > Pipeline of PD > aSyn - Antibody	note	md	4	0
20240722_184327	Pipeline of PD > aSyn - Antibody > aSyn - Small molecules	note	md	4	0
20240722_184330	Pipeline of PD > aSyn - Vaccine	note	md	1	3

5 sources; uncertain_span_count totals 23; embedded_image_count totals 9 (4 + 2 + 0 + 0 + 3). Four of the 9 body-embedded figure assets are on the PK/PD-model page (mechanism / epitope diagram, MEDI1341 capture-ELISA Figure 4, PK/PD model Figure 17, predicted plasma-profile / target-suppression Figure 18). The Clinical-studies page carries 2 embeds (MEDI1341 MAD free a-syn / human binding evidence; TAK-341 rat / NHP preclinical CSF a-syn evidence Figure 14). The cross-pipeline aSyn-Vaccine page carries 3 embeds (AFF008 study series). Figures are linked rather than re-embedded on this entity page per the 2026-04-29 body-purity decision; the figure-only embeds remain at the canonical by-photo level.

Figure / Asset Groups In Source

source	figure group
20240722_181818	TAK-341 mechanism and epitope diagram (residue map, post-translational modification site labels, fragment-antibody overlay); MEDI1341 capture-ELISA Figure 4 (Eu-counts vs Aggregate / Monomer / Blank for MEDI1341 / Aslo0543 / asyn0087); PK/PD model two-compartment diagram (Figure 17, plasma / CSF-brain with Ksyn / Kon / Koff / Kdeg / Kint); predicted plasma profile and target-suppression curves at four IV doses (Figure 18, multi-dose plasma concentration vs time and α-syn suppression %).
20240722_181822	MEDI1341 MAD Mean (SD) % Change from Baseline for Free a-synuclein in CSF evidence figure (slide 20220112 TAK-341 POM and Ph2 planning discussion - 011222); TAK-341 rat / NHP preclinical free / total CSF α-syn evidence (Figure 14, paired rat / monkey total / free panels).
20240722_184330	AFF008 study series figure (3 embedded image assets on the aSyn-Vaccine page); the SAD-study MEDI1341 PK plot itself is on the continuation page 20240722_184333 (delegated; not on this entity).

Uncertainties Carried From Source

issue	source
(Mazzulli et al. 2016, PMID) carryover top row PMID value is not visible in this photo.	20240722_181818
Mechanism diagram phosphorylation / glycosylation / ubiquitination site labels are too small at residue level; the source preserves them as image asset rather than exact residue-level transcription.	20240722_181818
α-synuclein amino-acid sequence block was transcribed from the visible sequence with OCR help; individual letters should be checked before using as a canonical sequence.	20240722_181818
Affinity-table KD exponents (1.38 x 10^-10, 3.73 x 10^-11, 9.30 x 10^-10, 7.38 x 10^-10, 6.23 x 10^-10, 1.22 x 10^-9) are tiny and should be checked against the image; the visible pM summary values 106 / 74 / 174 pM and 37.3-930 pM are the safer source-language anchors.	20240722_181818
Capture-ELISA clone IDs Aslo0543, asyn0087, and the IHC clone Aslo0452 (used in the MSA postmortem narrative) are flagged because OCR and image distinguish l / 1 / o poorly.	20240722_181818
Figure 18 right-side dose legend and target-suppression legend are small; doses were reconstructed from OCR plus visual evidence.	20240722_181818
Table 7 (Planned MEDI1341 Dose Escalations) only shows Cohort 1 and Cohort 5 in this photo; intermediate cohort rows are not visible and likely require adjacent photo evidence.	20240722_181818
nav_path TAK-341 (MEDI1341) > Clinical studies is inferred from visible nav headings and body content; active highlight is not clear enough to prove exact subsection.	20240722_181822
Top comparison table column headers are partly cut off at the top / left edge; the full schema must be recovered from adjacent photos.	20240722_181822
Prasinezumab MAD row cells 0.3 (w9) and ↓97% (the highest dose) are small and partially wrapped.	20240722_181822
TAK-341 POM mini-table dose rows and percent-change values (-47.2 / -47.3 %, -68.9 / -68.1 %, -86.5 %) are very small in the photo; values are preserved as figure evidence and only obvious fragments are transcribed.	20240722_181822
Preclinical-graph units Cmax of 2800 ng/mL and AUC∞ of 4100 ng*day/mL: OCR rendered the unit glyph poorly; visual reading suggests ng, but manual confirmation is needed.	20240722_181822
Clinical dose schema cohort tokens Cohort 2 (2400 mg) / Cohort 3 (4800mg) are clear in the crop but the photo angle and highlight make exact digits high-risk.	20240722_181822
MSA study row token FPI in 202207 may be shorthand for 2022-07; the left row label is partly cut by the next-page boundary.	20240722_181822
Pipeline-of-PD aSyn-Antibody / aSyn-Small molecules / aSyn-Vaccine pages carry several Uncertain Spans for token-list drug names, clipped result cells, and the visible-as-written drug-name fragment 200-11, 30599 (313), zasolmin /norvatis; row alignment for the eight-program comparison row should be checked against the canonical page before downstream extraction.	20240722_184324, 20240722_184327, 20240722_184330
The mAbs summary row label TAK-341 (MEDI1341/Aslo452ngl-3) preserves the third-clone token Aslo452ngl-3 verbatim; the trailing ngl-3 segment is not unambiguously legible in the photo.	20240722_184327
The MEDI1341 SAD-study PK table opens at the bottom of _184330 and continues into _184333; the _184333 page (Pipeline of PD GT) is delegated to clinical-pd and is not included in this entity’s Source Table. Readers needing the full PK table should follow the related-photo continuation note on the _184330 source.	20240722_184330

Related Pages

• alpha-synuclein — α-synuclein topic synthesis (Tier 1); the program-axis narrative for TAK-341 / MEDI1341 lives under § Antibody and Immunotherapy Programs.
• therapeutic-programs — program-routing map; this entity page is the canonical owner for the TAK-341 / MEDI1341 row that was previously listed as an Entity Backlog Candidate.
• tak-341-medi1341 — per-nav-root index for TAK-341 (MEDI1341) (1 source where the program is the first nav_path entry; the PK/PD-model page is indexed under Pipeline of GD & GBA-PD instead).
• gba-pd-asyn — section index containing all 5 sources used here.
• pipeline-of-pd — per-nav-root index for the cross-pipeline Pipeline of PD first- nav-root entry that anchors _184327 and _184330.
• pipeline-of-gd-and-gba-pd — per-nav-root index for the inherited-thread Pipeline of GD & GBA-PD first-nav-root entry that anchors _181818.
• alpha-synuclein-source-boundary — α-synuclein Tier 1 / Tier 2 / Tier 3 inclusion-and-delegation map; TAK-341 (MEDI1341) is under Programs and Standalone Nav-Roots.
• source-catalog — all 447 sources in capture order.
• nav-path-index — 376 distinct nav_paths.
• parkn-gt — sibling program entity (different modality class but same in-house program-entity precedent; the PARKN GT decision-matrix records that aSyn-related biomarkers are not planned for the program because aSyn pathology is rarely observed in the target population, which is the cross-program contradiction surfaced on alpha-synuclein § Parkin / PARKN GT ↔ aSyn Link).
• nlrp3-inhibitor — sibling program entity (small-molecule modality; same program-entity precedent).
• pr001 — pilot- scope GBA gene-therapy program entity (sibling within the GBA-PD pilot).